Please Share:: India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Indoco Remedies- Muted margins…
Indoco’s Q3FY11 sales increased 19.4% to | 114.3 crore in line with our
expectation of | 117 crore mainly driven by growth in formulation
exports and the domestic API business. However, at the EBITDA level,
margins were subdued at 12.7%, below our expectation of 15.1% due to
change in the product mix, increase in raw materials cost and fall in
realisation due to currency fluctuation. Increase in the taxation YoY
restricted the net profit growth to 14% to | 8.8 crore. We believe the
domestic formulation business will be normalised in due course. We
also expect a couple of products to be launched in semi-regulated
markets in Q4FY11. We have maintained our BUY rating on the stock.
Visit http://indiaer.blogspot.com/ for complete details �� ��
Indoco Remedies- Muted margins…
Indoco’s Q3FY11 sales increased 19.4% to | 114.3 crore in line with our
expectation of | 117 crore mainly driven by growth in formulation
exports and the domestic API business. However, at the EBITDA level,
margins were subdued at 12.7%, below our expectation of 15.1% due to
change in the product mix, increase in raw materials cost and fall in
realisation due to currency fluctuation. Increase in the taxation YoY
restricted the net profit growth to 14% to | 8.8 crore. We believe the
domestic formulation business will be normalised in due course. We
also expect a couple of products to be launched in semi-regulated
markets in Q4FY11. We have maintained our BUY rating on the stock.